anti-ACAN antibody product blog
Tags: Antibody; anti-ACAN antibody; ACAN; Monoclonal Antibody; Aggrecan, N-terminal neoepitope ARG;
The ACAN acan (Catalog #MBS442018) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The Monocloncal Antibody to ARG (Clone BC3) reacts with Human, rat, cat, cow, dog, guinea pig, horse, pig, rabbit, sheep. and may cross-react with other species as described in the data sheet. MyBioSource\'s Aggrecan, N-terminal neoepitope ARG can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB).Western Blot - Suggested dilution: 1:100. Detects a variety of epitopes between 50 and 250 kDa; ELISA; IHC with frozen sections or formalin/PFA-fixed paraffin embedded sections. Researchers should empirically determine the suitability of the ACAN acan for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The ACAN acan product has the following accession number(s) (GI #22209083) (NCBI Accession #AAH36445.1) (Uniprot Accession #P16112). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
During differentiation of neural precursor cells, neurospheres downregulate Chondroitin sulfate proteoglycans (CSPGs). Proliferating neural precursors synthesize lecticans, including aggrecan, which are downregulated with differentiation; suggesting a link between CSPGs and CNS precursor biology.
Aggrecan monoclonal antibody to N-terminal neoepitope ARG (mouse, clone BC-3). Aggrecan degradation products containing this neoepitope are rapidly released from the tissue in model explant culture systems and are also present in the synovial fluids of patients with degenerative joint disease.
Immunogen: ARGSV synthetic peptide conjugate.
Myeloma: x63-Ag8.653
Light Chain Type: kappa. Technical Notes: Samples must be deglycosylated using 0.01 Units Chondroitinase ABC (Sigma), 0.01 Units eratanase (Seikagaku) and 0.0001 Units Keratanase II (Seikagaku) per 10ug S-GAG of nondeglycosylated aggrecan for optimal epitope recognition. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing ACAN are readily searchable from our website. Different antibodies against the same target such as ACAN may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results. ACAN also interacts with the following gene(s): ADAMTS4, BMP2, FMOD, KERA, LUM, SOX9. The following patways have been known to be associated with this gene. Connective Tissue tissues are correlated with this protein.